Clinical trials have proven the magnetic fluid method to not be inferior to the radioisotope and dye method in breast cancer SLNB (Taruno K, et al ASCO 2018, J Clin Oncol 36, 2018 suppl:abstr e12603).Since the radioisotope method cannot be performed in many medical facilities in Japan, blue dye, fluorescent dye, or both are often… Read More: Ferucarbotran vs. RI/Dye Method »
Mikio Shiozawa, from the Department of Surgery at Jichi Medical University, describes the development of sentinel lymph node biopsy using magnetic fluid (RESOVIST®):“Since around 2007, I had been working at a small community hospital that did not have the facilities to perform the radioisotope method and I was contemplating alternative ways, like using magnetic fluids.… Read More: Development of SLNB using Magnetic Fluid »
TAKUMI – Matrix Cell Research Institute Inc.’s magnetic probe for sentinel lymph node detection – will be exhibited at the MEDICA Trade Fair 2019 held in Düsseldorf, Germany from November 18 to 21.Since having acquired CE Marking for TAKUMI at the beginning of July, the company announced that they are particularly looking forward to this year’s fair… Read More: TAKUMI at MEDICA 2019 »
Matrix Cell Research Institute Inc. has – effective as of July 1, 2019 – acquired CE Marking (Notified Body Number: 0344; EC Certificate No.: 4201663CE01) for TAKUMI in the European Union. Approval of CE Marking means that TAKUMI, the handheld magnetic probe for detection of magnetic fluid used to identify cancer metastases in Sentinel Lymph… Read More: CE Marking Acquired for TAKUMI Magnetic Probe »
From 1999 to 2002, a third phase of multicenter clinical trials, focusing on axillary lymph node dissection (ALND), was conducted: randomized comparisons between “ALND vs. omission of ALND” and “ALND vs. radiotherapy” were performed, analyzing their respective disease-free survival rate, overall survival rate and lymph node recurrence rate, including sentinel node-negative and sentinel node-positive cases.The… Read More: SLN Clinical Trial Phase »